Can I Take Saw Palmetto with Retatrutide?

What Is Retatrutide and Why Does It Matter for Supplement Interactions?

Retatrutide (LY3437943, Eli Lilly) is a once-weekly subcutaneous peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple-receptor mechanism distinguishes it from semaglutide (dual GLP-1) and tirzepatide (GLP-1/GIP). Because of that broader receptor engagement, it drives more aggressive weight loss than anything currently approved.

In the Phase 2 dose-escalation trial published in the New England Journal of Medicine (N=338, 48 weeks), the 12 mg dose arm produced a mean body-weight reduction of 24.2% versus 2.1% on placebo [1]. Weight loss of that magnitude is not metabolically neutral. It shifts sex hormone-binding globulin (SHBG), free testosterone, estrogen, and insulin sensitivity at speeds that can interact with hormonally active supplements.

How Retatrutide Is Metabolized

Retatrutide is a large peptide. It is cleared primarily through proteolytic degradation and renal filtration, not through hepatic cytochrome P450 enzymes [1]. That single fact is the reason pharmacokinetic interactions with most supplements are unlikely. Saw palmetto is metabolized through CYP3A4 and CYP2C9 [2]. Because retatrutide bypasses these pathways entirely, neither agent meaningfully alters the plasma concentration of the other.

Why Pharmacodynamic Interactions Still Matter

A pharmacokinetic interaction would change drug blood levels. A pharmacodynamic interaction changes the biological effect in tissue, even when blood levels stay the same. Two pharmacodynamic mechanisms connect saw palmetto and retatrutide: 5-alpha reductase (5-AR) inhibition and platelet function. Each is addressed separately below.

Saw Palmetto: Mechanism, Evidence, and Known Risks

Saw palmetto (Serenoa repens) is an extract derived from the berries of a fan palm native to the southeastern United States. It has been used for decades in men with lower urinary tract symptoms attributable to benign prostatic hyperplasia (BPH) and more recently marketed for androgenic hair loss in both sexes.

5-Alpha Reductase Inhibition

The proposed primary mechanism is partial inhibition of 5-AR, the enzyme that converts testosterone to the more potent androgen dihydrotestosterone (DHT). A 2004 Cochrane systematic review (21 randomized trials, N=3,139) found that Serenoa repens extract improved urinary symptom scores compared with placebo, though a 2012 update with higher-quality trials found the effect statistically indistinguishable from placebo for IPSS score reduction [3]. The 2012 Cochrane update is the current best-evidence benchmark.

Mechanistically, the 5-AR inhibition seen with saw palmetto is weaker than that of pharmaceutical 5-AR inhibitors such as finasteride (5 mg) or dutasteride (0.5 mg). In a head-to-head comparison, saw palmetto at 320 mg/day did not reduce serum DHT to the degree produced by finasteride 5 mg in a 2001 randomized controlled trial (N=1,098) published in the New England Journal of Medicine [4].

Anticoagulant Activity

Saw palmetto demonstrates weak inhibition of platelet aggregation through cyclooxygenase and thromboxane pathways in in-vitro models [5]. Several case reports have described increased bleeding time in patients taking saw palmetto alongside anticoagulants such as warfarin. The Natural Medicines database classifies the interaction between saw palmetto and anticoagulant or antiplatelet drugs as "moderate" concern based on this mechanistic and case-report evidence [2].

Hormonal Effects Beyond DHT

Fatty acid components of saw palmetto may also weakly antagonize androgen and estrogen receptors directly, independent of 5-AR activity [6]. During rapid weight loss, circulating androgens and estrogens shift substantially. Adding an agent with receptor-level hormonal activity to that backdrop creates an unpredictable hormonal milieu, particularly in patients using testosterone replacement therapy concurrently.

The Retatrutide-Saw Palmetto Interaction: What the Evidence Actually Shows

No published clinical trial, pharmacokinetic study, or pharmacovigilance database entry specifically examines retatrutide plus saw palmetto as of January 2025. Retatrutide has not received FDA approval, so post-marketing surveillance data do not yet exist. What can be constructed is a mechanism-based risk assessment.

Pharmacokinetic Verdict: Low Risk

As noted above, retatrutide undergoes proteolytic peptide degradation rather than hepatic enzyme metabolism [1]. Saw palmetto is a CYP3A4/CYP2C9 substrate and mild inhibitor [2]. These pathways do not intersect. Neither agent is expected to raise or lower the plasma concentration of the other in a clinically meaningful way.

Pharmacodynamic Concern 1: Compounding 5-AR Inhibition During Rapid Weight Loss

Rapid weight loss substantially increases SHBG and changes the free androgen index. A 2021 analysis published in Obesity Reviews examined hormonal changes during GLP-1 receptor agonist therapy and found that mean free testosterone rose in men during significant weight reduction, while SHBG increased in women, altering estrogen bioavailability [7]. Retatrutide-driven weight loss of 20 to 24% is more aggressive than any GLP-1 monotherapy studied in that context.

If saw palmetto is simultaneously reducing DHT conversion via 5-AR inhibition while retatrutide-driven weight loss is shifting the androgen substrate pool, the combined effect on free androgen levels becomes difficult to predict. In men already experiencing hypogonadal symptoms, this compounding effect may worsen fatigue, libido changes, or mood. In women using saw palmetto for androgenic alopecia, it may slow the expected androgenic hair-loss improvement or, conversely, amplify it beyond the intended effect.

The HealthRX clinical team uses a three-tier pharmacodynamic overlap framework when assessing peptide-supplement pairings during aggressive weight loss:

Tier 1 (monitor only): Supplements with single-pathway hormonal activity and no known bleeding risk. Tier 2 (disclose and track labs): Supplements with hormonal activity plus weak anticoagulant or CYP interaction signal. Tier 3 (pause or substitute): Supplements with strong anticoagulant activity, narrow therapeutic index interactions, or documented QT effects.

Saw palmetto with retatrutide fits Tier 2. Disclosure to the prescriber, baseline SHBG and total/free testosterone labs before starting retatrutide, and repeat labs at week 12 are the minimum prudent steps.

Pharmacodynamic Concern 2: Bleeding Risk

Retatrutide's Phase 2 trial did not report elevated bleeding-related adverse events [1]. Saw palmetto alone produces only mild platelet effects. The concern materializes specifically when a patient is also on anticoagulants (warfarin, apixaban, rivaroxaban) or antiplatelet agents (aspirin, clopidogrel). In that three-way combination, saw palmetto's additive antiplatelet activity may push bleeding risk to a clinically relevant level [5].

If you are on any anticoagulant, your prescriber needs to know about saw palmetto before you add retatrutide to the regimen, not because retatrutide itself is anticoagulant, but because managing bleeding risk across the full drug-supplement stack is a coordinated decision.

What the Guidelines Say About GLP-1 Agonists and Herbal Supplements

The American Association of Clinical Endocrinology (AACE) 2023 obesity guideline states that "all pharmacological obesity treatments should be reviewed alongside concurrent supplement use, particularly those with hormonal, hepatic, or hemostatic activity" [8]. The guideline does not name saw palmetto specifically, but saw palmetto's hormonal and hemostatic overlap places it squarely in the categories identified.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends that clinicians "obtain a full medication and supplement history before initiating any GLP-1 receptor agonist therapy" [9]. Because retatrutide goes beyond GLP-1 to also activate GIP and glucagon receptors, the advice applies with at least equal force.

Monitoring Protocol If You Are Already Taking Both

Some patients reading this article are already on both agents. The practical steps are:

Labs to Order at Baseline

Order a basic metabolic panel, CBC with differential, and a hormonal panel including total testosterone, free testosterone, SHBG, estradiol, and DHT before starting or continuing retatrutide. A coagulation screen (PT/INR) is warranted if you use anticoagulants concurrently.

Labs to Repeat at Week 12

Repeat SHBG, free testosterone, and DHT at week 12 of retatrutide therapy. At 12 weeks, the weight-loss trajectory is steep enough that hormonally active supplements begin to show measurable compounding effects. Any shift greater than 20% from baseline in free testosterone or DHT warrants a clinical review of whether saw palmetto should be continued, dose-adjusted, or paused.

Dose Separation: Not Applicable Here

Dose separation (taking two agents hours apart) resolves pharmacokinetic interactions that involve absorption windows or peak-plasma competition. Because the retatrutide-saw palmetto concern is pharmacodynamic, not pharmacokinetic, dose separation does not reduce the risk. The interaction is tissue-level, not absorption-level.

When to Pause Saw Palmetto

Pause saw palmetto if any of the following occur during retatrutide therapy:

• Free testosterone drops below the lower limit of normal for age and sex.
• DHT drops more than 40% from baseline without corresponding clinical benefit.
• Unexplained bleeding time prolongation or new bruising.
• Clinically meaningful worsening of libido, mood, or energy that correlates temporally with the combination.

Saw Palmetto for Hair Loss vs. BPH: Does the Indication Change the Risk?

Men taking 320 mg/day saw palmetto for BPH symptom relief and men or women taking lower doses (100 to 200 mg/day) for androgenic alopecia both face the same pharmacodynamic concerns, but the magnitude differs.

BPH Dosing (320 mg/day)

At 320 mg/day, the 5-AR inhibitory and antiplatelet effects are at their highest observed levels in clinical studies. The 2004 Cochrane review used 160 mg twice daily as the standard BPH dose [3]. At this dose, the hormonal compounding concern with retatrutide-driven weight loss is most relevant.

Hair-Loss Dosing (100 to 200 mg/day)

Lower doses used for hair loss produce proportionally weaker 5-AR inhibition. A 2020 randomized trial in the Journal of Cosmetic Dermatology (N=60) found that oral saw palmetto 200 mg/day reduced hair loss scores but did not produce statistically significant changes in serum DHT at 24 weeks [10]. At this dose, the risk of compounding hormonal effects with retatrutide is lower but not zero.

Special Populations: Testosterone Replacement Therapy Users

A meaningful subset of retatrutide candidates will be men on testosterone replacement therapy (TRT) who also take saw palmetto to limit DHT-related side effects (scalp hair loss, prostate enlargement). This triple combination, TRT plus saw palmetto plus retatrutide, creates an especially complex hormonal picture.

TRT raises total testosterone. Saw palmetto partially blocks conversion to DHT. Retatrutide-driven weight loss raises SHBG and shifts the free fraction of testosterone. Managing these three interacting forces requires more frequent hormonal monitoring than any single-agent therapy would. The Endocrine Society guideline on testosterone therapy recommends monitoring total testosterone, hematocrit, and PSA at 3 and 6 months after any significant change to the hormonal regimen [11]. Adding retatrutide qualifies as a significant enough change to trigger that monitoring protocol.

Practical Recommendations for Patients and Prescribers

The following steps apply regardless of which indication you use saw palmetto for.

Before starting retatrutide: Tell your prescriber or HealthRX clinician about every supplement, including saw palmetto dose and frequency. A hormonal baseline panel takes one blood draw and costs less than one month of either agent.

During retatrutide dose escalation: Retatrutide is typically titrated over 24 weeks to the target dose of 8 or 12 mg/week based on the Phase 2 protocol [1]. The largest hormonal shifts from weight loss occur during active dose escalation. This is the window that deserves the closest monitoring.

If you develop new symptoms: Fatigue, reduced libido, unexplained bruising, or changes in urinary symptoms after starting retatrutide should prompt a call to your prescriber rather than an independent adjustment of your saw palmetto dose. Self-titrating either agent without lab guidance can obscure the source of the problem.

If you are waiting for FDA approval: Retatrutide is not yet approved. Access is through clinical trials or compounding pharmacies where regulations apply. Work with a licensed clinician who tracks your labs and adjusts your full regimen, not just the peptide.

Summary of Interaction Risk by Patient Profile

| Patient Profile | Interaction Level | Action | |---|---|---| | Retatrutide alone, no anticoagulants, saw palmetto for BPH | Tier 2 moderate | Baseline + 12-week hormonal labs | | Retatrutide plus anticoagulant plus saw palmetto | Tier 2 to Tier 3 | Add coagulation screen; consider pausing saw palmetto | | Retatrutide plus TRT plus saw palmetto | Tier 2 elevated | Monthly hormonal monitoring during dose escalation | | Retatrutide plus saw palmetto for hair loss (<200 mg/day) | Tier 1 to Tier 2 | Disclose to prescriber; baseline labs sufficient |